Novartis Reports Nine Tumor Cases in Zolgensma Patients
Novartis said it received nine reports of tumors in patients treated with Zolgensma since the gene therapy was approved in 2019. Two cases had evidence linking them to the medicine; both patients underwent treatment and continue to be monitored.
By Adria CalatayudNovartis said it received nine reports of tumors in patients treated with its gene therapy Zolgensma since the drug was approved in 2019, including two with evidence linking them to the medicine.The Swiss drugmaker said both patients underwent treatment and continue to be monitore…